Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Italian Stock Exchange  >  Recordati    REC   IT0003828271

RECORDATI (REC)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 09/26 05:11:23 pm
29.43 EUR   +0.24%
09/12The ninth edition of the international prize for scientific resea..
GL
07/26RECORDATI : Half-year results
CO
07/02RECORDATI : says CVC offer includes any dividend
RE
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   End-of-day quote. End-of-day quote Italian Stock Exchange
09/19/2018 09/20/2018 09/21/2018 09/24/2018 09/25/2018 Date
29.67(c) 29.46(c) 29.35(c) 29.12(c) 29.36(c) Last
231 381 336 783 556 848 196 694 367 357 Volume
-0.44% -0.71% -0.37% -0.78% +0.82% Change
More quotes
Financials (EUR)
Sales 2018 1 367 M
EBIT 2018 442 M
Net income 2018 313 M
Debt 2018 436 M
Yield 2018 3,14%
Sales 2019 1 432 M
EBIT 2019 467 M
Net income 2019 334 M
Debt 2019 280 M
Yield 2019 3,29%
P/E ratio 2018 19,38
P/E ratio 2019 18,26
EV / Sales2018 4,81x
EV / Sales2019 4,48x
Capitalization 6 140 M
More Financials
Company
Recordati SpA engages in the research, development, manufacturing and marketing of pharmaceuticals.It operates through two segments: Pharmaceutical and Rare Diseases.The Pharmaceutical segment offers prescription and over-the-counter products as well as chemical syntheses, intermediates, and active... 
Sector
Pharmaceuticals
Calendar
10/30Earnings Release
More about the company
Surperformance© ratings of Recordati
Trading Rating : Investor Rating :
More Ratings
Latest news on RECORDATI
09/12The ninth edition of the international prize for scientific research arrigo r..
GL
07/26RECORDATI : Half-year results
CO
07/02RECORDATI : says CVC offer includes any dividend
RE
06/29RECORDATI : CVC buys majority of drugmaker Recordati, to launch takeover
RE
06/29RECORDATI : CVC Fund VII Acquires Controlling Stake in Recordati S.p.A.
PU
06/11RECORDATI : Acquires natural point s.r.l. in italy
GL
05/17EXCLUSIVE - CVC PUTS $9 BILLION RECO : sources
RE
05/08RECORDATI : Announces sales and margin growth in the first quarter 2018. revenue..
GL
04/23RECORDATI : Ex-dividend day for final dividend
FA
04/18RECORDATI : Press Release
CO
More news
Sector news : Pharmaceuticals - NEC
01:30pTSX futures higher ahead of expected U.S. rate hike
RE
01:23pKENNETH FRAZIER : Merck's Frazier to remain CEO beyond 2019
RE
01:07pALEXION PHARMACEUTICALS : to Buy Syntimmune for Up to $1.2 Billion
DJ
08:15aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/25EUROPE : Oil boost and Italy budget hopes support European shares
RE
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on RECORDATI 
RECORDATI - 01/22
In an accumulation phase
BUY
RECORDATI SPA - 2016
A medium term support level to take advantage of
BUY
More Strategies
Latest Tweets
09/07$REC #Recordati RECORDATI - Everything must change so that nothing changes: |.. 
07/26RECORDATI ANNOUNCES SALES AND MARGIN GROWTH IN THE FIRST HALF 2018. REVENUES .. 
07/24$REC Recordati : Feedback from road show with CFO: with CVC, pursuit of the .. 
07/02Recordati’s take-under is a painful reality check. Minority shareholders must..
2
07/02Italian pharma group #Recordati take-under is painful reality check - ready s..
2
More tweets
Qtime:34
News from SeekingAlpha
07/26Recordati Industria Chimica e Farmaceutica S.p.A. 2018 Q2 - Results - Earning.. 
06/11Recordati acquires Natural Point S.R.L. 
06/07Recordati (RCDTF) Presents At Jefferies 2018 Global Healthcare Conference - S.. 
05/24RECORDATI : A Somehow Boring But Interesting Pharmaceutical Company 
05/08Recordati Industria Chimica e Farmaceutica reports Q1 results 
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 35,8 €
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Andrea Recordati Vice Chairman & Chief Executive Officer
Alberto Recordati Chairman
Fritz Squindo Chief Financial Officer, Executive Director & MD
Mario Garraffo Independent Non-Executive Director
Marco Vitale Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
RECORDATI-21.42%7 222
JOHNSON & JOHNSON2.26%371 937
PFIZER20.90%256 702
NOVARTIS-0.63%219 947
ROCHE HOLDING LTD.-4.20%211 344
MERCK AND COMPANY25.79%187 895